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Increased eukaryotic translation initiation factor 4E (eIF4E) expression occurs in many cancers, and makes fundamental contributions
to carcinogenesis by stimulating the expression of cancer-related genes at post-transcriptional levels. This key role is highlighted by the
facts that eIF4E levels can predict prognosis, and that eIF4E is an established therapeutic target. However, eIF4E activity is a complex
function of expression levels and phosphorylation statuses of eIF4E and eIF4E-binding proteins (4E-BPs). Our hypothesis was that the
combined analyses of these pathway components would allow insights into eIF4E activity and its influence on cancer. We have
determined expression levels of eIF4E, 4E-BP1, 4E-BP2 and phosphorylated 4E-BP1 within 424 breast tumours, and have carried out
analyses to combine these and relate the product to patient survival, in order to estimate eIF4E activity. We show that this analysis
gives greater prognostic insights than that of eIF4E alone. We show that eIF4E and 4E-BP expression are positively associated, and
that 4E-BP2 has a stronger influence on cancer behaviour than 4E-BP1. Finally, we examine eIF4E, estimated eIF4E activity, and
phosphorylated 4E-BP1 as potential predictive biomarkers for eIF4E-targeted therapies, and show that each determines selection of
different patient groups. We conclude that eIF4E’s influence on cancer survival is modulated substantially by 4E-BPs, and that
combined pathway analyses can estimate functional eIF4E.
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The eukaryotic translation initiation factor 4E (eIF4E) has key
roles in carcinogenesis (De Benedetti and Graff, 2004). eIF4E is
often overexpressed in carcinoma cells as compared to equivalent
normal epithelium in many tumour types including breast
(Kerekatte et al, 1995), lung (Rosenwald et al, 2001) and colon
(Rosenwald et al, 1999). The oncogenic role of this overexpression
has been shown by various experimental observations; for
example, forced eIF4E overexpression within many cell types
leads to transformation (De Benedetti and Graff, 2004), and within
transgenic mice increases incidence of multiple tumour types
(Ruggero et al, 2004). eIF4E has at least two normal cellular
functions. First, it is an essential component of the multimeric
factor eIF4F, which initiates cap-dependent translation – the
mechanism responsible for most protein synthesis (Gray and
Wickens, 1998). eIF4E’s role is to bind to mRNA caps allowing
recruitment of eIF4F, and subsequently the translational machin-
ery. The complex formed scans linearly along the 50 untranslated
region (UTR) until an initiation codon in good context is
encountered, at which point further elements of translational
machinery are recruited and protein synthesis starts. Second,
eIF4E regulates expression of some genes by controlling nuclear
export of their transcripts (Culjkovic et al, 2007), a function that
also requires eIF4E’s cap-binding activity (Culjkovic et al, 2005).
Under most normal conditions, availability of active eIF4E is
thought to be rate limiting for both functions. One might expect
a general translational stimulation to result from the increased
eIF4E expression in cancers, on account of enhanced mRNA cap
recognition, yet effects of eIF4E overexpression are more subtle.
Approximately 10% of mammalian transcripts have 50UTRs that
may form complex secondary structures that reduce the abilities of
both eIF4F to bind to mRNAs and the translational machinery to
scan 50UTRs (Pesole et al, 2001); the result is that these transcripts
are translated inefficiently (Hughes, 2007). The majority of human
transcripts with these inhibitory 50UTRs code for growth or
cancer-associated proteins (Kozak, 1991). Increased eIF4E is
thought to reduce the effects of 50UTR structure by enhancing
cap-recognition and scanning, therefore increasing translation of
these specific oncogenic transcripts (De Benedetti and Graff, 2004).
Similarly, increased eIF4E expression enhances nuclear export of a
set of transcripts associated with oncogenesis (Culjkovic et al,
2007). As a consequence of this central role, eIF4E is an established
target for cancer therapy (Smolewski, 2006; Graff et al, 2008).
The importance of eIF4E in cancer has been underlined by the
fact that eIF4E expression levels can be used to determine
prognosis. Cases in which eIF4E is highly overexpressed tend to
have poor prognoses (Li et al, 1998). A substantial confounding
factor is that eIF4E expression does not equate to eIF4E activity,
thereby making interpretation of potential influences of eIF4E
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slevels difficult. eIF4E activity is a complex function of eIF4E
expression and expressions and activities of eIF4E-binding
proteins (4E-BP1, 2 and 3) that bind to and inhibit eIF4E (Richter
and Sonenberg, 2005) (Supplementary Figure S1). Activity is
further regulated by phosphorylation of 4E-BP1 (and other 4E-BPs
it is assumed), with only hypophosphorylated forms being able
to inhibit eIF4E. Additional regulation occurs by differential
phosphorylation of eIF4E itself, although there are conflicting
reports as to how this influences activity (Scheper and Proud,
2002). The result is that high expression of eIF4E may not lead to
high eIF4E activity if, for example, hypophosphorylated 4E-BP1
were also highly expressed. Many cancer-related signalling path-
ways, including PI3K and p38, converge to regulate eIF4E and
4E-BP phosphorylation; therefore, eIF4E activity seems to be a key
cancer-signalling node (Polunovsky and Bitterman, 2006). Here,
we have tested the hypothesis that combined analyses of
expressions and phosphorylation states of eIF4E, and its regulators
allows greater understanding of eIF4E activity and its influence on
cancer than examination of eIF4E expression alone.
MATERIALS AND METHODS
Patients
Ethical approval was obtained (Leeds East 05/Q1206/136). Archival
cancer tissue and data were obtained for 424 patients diagnosed at
LTH NHS Trust from 1983–2006. Tissue microarrays (TMAs) were
constructed containing 0.6mm cores selected from representative
tumour areas as determined by a consultant breast histopatho-
logist (AMS) from H&E stained sections. Survival periods –
overall: initial diagnosis to death; disease-free: initial diagnosis to
the diagnosis of recurrence/metastasis; disease-specific: initial
diagnosis to death after recurrence or metastasis (cancer-specific
death confirmed in most cases).
Westerns and immunohistochemistry
MCF7 and MDA-MB-231 cells were cultured/transfected as earlier
(Johnson et al, 2008; Maraqa et al, 2008). An eIF4E expression
vector was obtained from John Blenis (Harvard Medical School)
and Nahum Sonenberg (McGill). Western analyses were carried
out as earlier (Maraqa et al, 2008) using the reagents in
Supplementary Table S1. TMA sections of 5mm were dewaxed
and blocked in hydrogen peroxidase block (20min). Antigens were
retrieved and stained as described in Supplementary Table S1, and
as used elsewhere (Zhou et al, 2004; Dutton et al, 2005; Lee et al,
2005; Engelman et al, 2008). Envision detection was used (DAKO,
Glostrup, Denmark). Negative controls (primary antibodies
omitted) were included in each immunohistochemistry (IHC)
batch; in addition, adjacent normal epithelium, lymphocytes and
blood vessel endothelium served as internal controls. Controls
were performed for p4E-BP1 antibodies in which sections were
pretreated with Lambda Phosphatase (Nebraska, NE, USA). Cores
were scored for immunoreactivity by two or more individuals (LJC,
TJT, ETV and RAB), taking into account the average intensity and
percentage of positively stained tumour cells (as used earlier for
eIF4E (Zhou et al, 2006)). Staining intensity scores (0 no staining,
1 weak, 2 moderate and 3 strong) were added to percentages
positively stained scores (1 o5%; 2, 6–25%, 3, 26–75% and 4
475%), giving totals of 0 or 2–7. Consensus scores were determined
for cores with different initial scores, and all scoring was overseen by
a consultant breast histopathologist (AMH).
Mathematical analyses
Data were analysed using Kaplan–Meier survival curves. Depen-
dence on prognostic indicators was determined using Cox propor-
tional hazards models; significance values relate to likelihood ratio
tests of the null hypothesis that indicators do not effect hazard
rates (Cox and Oakes, 1984). SPSS (SPSS, Chicago, IL, USA) and
the Statistics Toolbox in MATLAB (ecdf.m and coxphfit.m)
(MathWorks, Natick, MA, USA) were used. Tests were two sided
and Po0.05 was considered significant.
RESULTS
Antibody validation
We have used IHC to determine expression levels in breast
tumours of the main regulatory molecules of the eIF4E pathway
– namely, eIF4E, 4E-BP1, 4E-BP2 and phosphorylated 4E-BP1
(Thr37/46) (termed p4E-BP1). We have not examined 4E-BP3
because it is not thought to have a role in breast (Poulin et al,
1998), or phosphorylated forms of eIF4E, as their influences on
the activity and in cancer remain uncertain (Scheper and Proud,
2002; Salehi and Mashayekhi, 2006; Buxade et al, 2008). First,
we optimised the antibody use on archival breast tissue. We
established that antibodies were specific for their antigens using
western blots against lysates of breast cancer cell lines (Supple-
mentary Figure S2A). In addition, we showed phospho-specificity
of antibodies against p4E-BP1 by carrying out IHC on serial tissue
sections with and without pretreatment with protein phosphatase
(Supplementary Figure S2B).
Patient cohort and immunohistochemistry
Tissue micro-arrays containing samples from 424 breast tumours
were established, supported by detailed clinicopathological data
(Supplementary Table S2). The cohort included a wide range of
patient and tumour characteristics, with mean patient follow-up of
91.9 months. We carried out IHC for eIF4E, 4E-BP1, 4E-BP2 and
p4E-BP1 on TMA sections and assessed immunoreactivity within
tumour cells, taking into account the proportions of cells staining
positively and average intensity, giving scores of 0 (negative) or
2–7 (positive). Representative staining patterns are shown
(Figure 1, and at higher magnification in Supplementary Figure
S3). Tumour stroma and normal tissue were negative for eIF4E,
4E-BP1 and 4E-BP2, whereas very occasional low-intensity staining
for p4E-BP1 was noted in normal epithelial cells. Staining was
generally cytoplasmic, although nuclear staining was noted in a
minority of cases (Supplementary Figure S4); this was separately
analysed and was found not to be of prognostic value and is not
discussed. As expected, data were not available for some patients
because of the TMA core loss during processing, a well-recognised
occurrence, therefore, data for all four antigens were available for
only 282 patients. The full range of scores were observed for each
antigen (Figure 1I). It was notable that staining was most
frequently not detectable for p4E-BP1. Others have reported more
frequent expression of p4E-BP1 (Zhou et al, 2004), therefore we
carried out IHC for an alternative p4E-BP1 species (Ser65); we
found immunoreactivity with this antibody to be similarly
infrequent (see discussion).
Expressions of eIF4E and 4E-BPs correlate with grade
Associations between antigen expressions and a wide range of
clinicopathological parameters were examined. No correlations
were found with nodal status, tumour size or histological type.
Weak positive/borderline no correlations were found with oestro-
gen receptor a status and eIF4E expression (Spearman’s
r coefficient 0.21; Po0.001) and 4E-BP2 (0.22; Po0.001), but
not with 4E-BP1 or p4E-BP1. Strong correlations between
expression of markers and tumour grade were found. eIF4E
expression (split into three classes, 0–3, 4–5 and 6–7) was
positively associated with grade (w
2-test, P¼0.011), whereas
expression of both 4E-BPs was negatively associated with grade
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s(4E-BP1 P¼0.002; 4E-BP2 P¼0.029). p4E-BP1 was positively
associated with grade (P¼0.012). A positive association between
eIF4E expression and grade has been reported earlier (Li et al,
2002). Correlations for other markers were consistent with their
influences on carcinogenesis being through the eIF4E pathway; 4E-
BPs, eIF4E inhibitors, were negatively associated with grade,
whereas 4E-BP1 phosphorylation, which would relieve 4E-BP1-
induced inhibition of eIF4E, was positively associated.
High expression of eIF4E correlates with poor prognosis
Kaplan–Meier survival analyses were used to determine survival
with respect to eIF4E. Analyses were carried out with expression
divided into IHC scores, although scores of 0, 2 and 3 were
combined as each individual group was small, for overall survival
(OS), disease-free survival (DFS) and disease-specific survival
(DSS) (Figure 2A–C). High eIF4E scores were indicative of poor
prognosis. Prognosis seemed to worsen with each increasing eIF4E
score for OS, whereas patterns for DFS and DSS suggested weaker,
but still detectable, influences of individual scores with an overall
grouping into two classes (0–5 good prognosis; 6 or 7 poor
prognosis). We have examined relationships between eIF4E
expression and survival using Cox regressions. We have included
either eIF4E scores, or eIF4E expression dichotomised arbitrarily
or as suggested by the apparent bimodal distribution seen above,
and modelled these with respect to OS, DFS and DSS. Models that
most accurately reflected the data included eIF4E scores rather
than dichotomised data, showing the value of scoring proportion
and intensity of positive tumour cells. In these models each
increase of 1 in eIF4E score gave increases in hazard ratios
(HRs) of 1.22 (P¼0.004), 1.3 (P¼0.008) and 1.33 (P¼0.005) for
OS, DFS and DSS, respectively. Thus individuals with scores of
7 have DFS HRs of 6.15 (95% CIs: 3–12, P¼0.008) as compared
with individuals with scores of 0. The prognostic value of
eIF4E has been reported earlier as independent of grade/nodal
status in breast cancer (Li et al, 1998); we have examined
independence from the Nottingham Prognostic Index (NPI), which
takes account of tumour size, grade and lymph node status
(Haybittle et al, 1982). In multivariate Cox regressions the
prognostic value of eIF4E was independent of NPI with eIF4E
remaining significant for OS (NPI Po0.00001; eIF4E P¼0.02),
DFS (NPI Po0.00001; eIF4E P¼0.045) and DSS (NPI Po0.00001;
eIF4E P¼0.029).
Prognostic value of 4E-BP1, 4E-BP2 and p4E-BP1
Kaplan–Meier survival analyses were also used to determine
survival with respect to the other markers. We present data
7 6 5 4 3 2 0 7 6 5 4 3 2 0 7 6 5 4 3 2 0 7 6 5 4 3 2 0
Phospho-4E-BP1
0
50
100
150
200
250
4E-BP2 4E-BP1 elF4E
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
F
r
e
q
u
e
n
c
y
5.8
2.4
4.6
16.2
31.8
25.4
13.8
7.4
2.4
4.4
15.7
21.9
25.7
22.5
10.1
0.6
3.2
15.2
29.7
24.7
16.5
3.1
62.3
5.0
8.4
11.8
5.2 4.2
Phospho-4E-BP1 4E-BP2
elF4E 4E-BP1
AB CD
H G F E
I
Figure 1 The full range of expression intensities and proportions for eukaryotic translation initiation factor 4E (eIF4E), eIF4E-binding protein (4E-BP) 1,
4E-BP2 and p4E-BP1 occur within breast cancers. (A–H) Representative tumour tissue microarray cores showing immunoreactivity as labelled. These cores
were scored A 4, B 7, C 3, D 7, E 3, F 7, G 3 and H 7. (I) Histograms showing distributions of immunohistochemistry scores within breast cancers. Scores
(x-axis) and numbers of cores assigned to each score (y-axis) are shown. Percentages of the cohort are given above the bar for each score.
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sfor DFS (Figure 2D–F), and for OS and DSS (Supplementary
Figure S5). These antigens provided little prognostic insight and
we were unable to construct significant Cox equations to model
their individual survival influences. In the case of 4E-BP2, there
was a nonsignificant trend for high scores to associate with good
prognosis.
Mathematical modelling of influences of 4E-BPs: 4E-BPs
modify eIF4E activity and provide additional prognostic
insights
Next we examined influences of 4E-BPs in the context of eIF4E
expression. We necessarily restricted these analyses to the 282
patients for whom scores of all four antigens were available. Using
this dataset, models including solely eIF4E expression gave HRs of
1.21 (P¼0.011), 1.24 (P¼0.035) 1.27 (P¼0.02) for OS, DFS and
DSS, respectively, for each increase of 1 in eIF4E score. We were
unable to construct significant Cox models on the basis of
combinations of 4E-BPs without including eIF4E, suggesting that
eIF4E is their critical effector. We found models combining
expression of 4E-BP1 or p4E-BP1 (as IHC scores, or dichotomised
into two groups) with eIF4E, provided little additional prognostic
value over that found with eIF4E alone. However, including
4E-BP2 in a model for OS enhanced the model significantly with
hazard increasing by 1.28 with each point increase in eIF4E score
(P¼0.005) and decreasing 0.11 with each increase in 4E-BP2 score
(P¼0.02). We refined this by combining eIF4E and 4E-BP2 scores
into a single non-linear variable in which high levels of eIF4E or
4E-BP2 act to increase or decrease the value respectively (achieved
using max (0,X-B2/3.5), where X and B2 represent eIF4E and 4E-
BP2 scores). This variable, termed ‘y’, predicted survival more
accurately than examination of eIF4E alone; each increase of 1 in
y carried HRs of 1.32 (P¼0.0003), 1.32 (P¼0.013) and 1.36
(P¼0.006) for OS, DFS and DSS, respectively. We also investigated
Cox models including expression of all four antigens. In order to
combine terms, we considered models that included each variable
separately and found their relative effect on HRs using maximum
likelihood estimation. Although individual components were not
statistically significant and had only little effects on likelihoods
(with the exception of eIF4E), a combination gave improved
prognostic power. This variable termed ‘z’ can be described as
X–B1/4þPB1/2-B2/4, where B1 and PB1 represent 4E-BP1 and
p4E-BP1. Each increase of 1 in z gave HRs of 1.15 (P¼0.006), 1.26
(P¼0.002) and 1.28 (P¼0.0008) for OS, DFS and DSS, respec-
tively. This variable has a highly significant relationship with
survival but this should be treated with caution because the
constants were determined using regressions for OS, and, thus to
an extent, significance is self fulfilling, at least for OS. The utility
of z, however, is supported by the fact that its relationship with
survival is more significant with DFS and DSS than OS, a result
not predetermined by the approach. We also examined whether
y or z give prognostic insights independently of NPI using
multivariate analyses. NPI and either y or z remain significant
in models for DFS (NPI Po0.00001; yP¼0.04 or zP¼0.03) and
DSS (NPI Po0.00001; yP¼0.02 or zP¼0.02).
The statistical significance of relationships of y and z with
survival show additional prognostic value from examining multi-
ple eIF4E pathway components. In addition, we have shown the
value of these variables using Kaplan–Meier analyses. First, we
focused on patients with high eIF4E scores (6 or 7), as it is in this
context that differential expression of 4E-BPs would be most
relevant. Patients with eIF4E scores 6 or 7 have a relatively poor
prognosis (Figure 2A–C), but no difference was detected between
groups scored as 6 or 7 in terms of DFS (Figures 2B and 3A). When
y was applied to this cohort some discrimination occurred with
improved prognosis for patients whose y scores were lowered by
4E-BP2 (Figure 3B), although the discrimination remained
statistically nonsignificant. When z was applied to this cohort
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Figure 2 Expression of eukaryotic translation initiation factor 4E (eIF4E), but not eIF4E-binding protein (4E-BP) 1, 4E-BP2 or p4E-BP1, is associated with
prognosis. (A–C) Kaplan–Meier survival analyses for overall (A), disease-free (B) and disease-specific survival (C) for patient groups with tumours with
differing eIF4E scores. (D–F) Kaplan–Meier survival analyses for disease-free survival for patient groups with tumours with differing scores for 4E-BP1 (D),
4E-BP2 (E) or p4E-BP1 (F). As scores of 0, 2 and 3 were relatively rare, these have been grouped together. Censoring ticks have been omitted for clarity.
eIF4E activity predicts breast cancer survival
LJ Coleman et al
1396
British Journal of Cancer (2009) 100(9), 1393–1399 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sfurther discrimination occurred (Figure 3C) showing how 4E-BPs
affect patient outcome through eIF4E. Second, we have focused on
patients with high NPI (and consequently poor DFS, Supplemen-
tary Figure S6). These patients were further stratified according to
eIF4E expression (cutoff 5.5 as suggested by the distribution in
Figure 2B) into separate groups (Figure 3D). As before, when z was
applied (Figure 3F) further discrimination occurred allowing
identification of patients with very poor (high z), or relatively
good prognosis (low z). In this case, z discriminated into
statistically significantly different groups (Figure 3F Log rank
P¼0.039) when use of eIF4E alone was not significant (Figure 3D
Log rank P¼0.15). In this case y was substantially less successful
as a prognostic indicator (Figure 3E Log rank P¼0.5) showing the
importance of combining all four components.
Expressions of eIF4E and 4E-BPs are positively associated
Although including assessments of 4E-BPs provided additional
prognostic information over that from only eIF4E, we were
surprised that influences of 4E-BPs, especially of 4E-BP1, were
relatively weak. One explanation for this was that expression levels
of eIF4E and 4E-BPs were not independent of each other. This
would mean that that at a given eIF4E level, differential expression
of 4E-BPs – therefore differential modification of eIF4E activity
– would be relatively rare, thereby minimising apparent influences
of 4E-BPs in our analyses. Associations between marker expres-
sions were examined using Spearman’s correlation tests (Table 1).
eIF4E expression showed moderate positive associations with
expression of both 4E-BPs (Po0.0001), although weak positive/no
association with p4E-BP1. Expression of 4E-BPs was also mode-
rately positively associated with each other (P¼0.02). Expression
of p4E-BP1 was positively associated with 4E-BP1 (Po0.0001)
(expected as 4E-BP1 must be expressed to be phosphorylated).
eIF4E activity scores are potential biomarkers for
eIF4E-targeted therapies
The eIF4E pathway is a target for cancer therapy with drugs
that either inhibit eIF4E activity indirectly (mTOR inhibitors
that reduce 4E-BP1 phosphorylation thereby inhibiting eIF4E
(Smolewski, 2006)), or directly (by binding to/reducing expression
of eIF4E (Graff et al, 2008)). However, a concern with these agents
is toxicity resulting from general translational repression. Conse-
quently, selection of patients who are most likely to benefit from
such agents using predictive biomarkers may aid their efficacy.
Three selection criteria are apparent: individuals with highest
eIF4E levels, highest eIF4E activities or highest levels of
phosphorylated 4E-BP1 (especially relevant for mTOR inhibitors
as these act by reducing 4E-BP phosphorylation). We have
compared selection of potential treatment groups using these
criteria from our cohort for whom scores of all four antigens were
available: first (group 1), those with eIF4E scores of 7 (37/282;
13.1%); second (group 2), those with high estimated pathway
activities (zX5.75, cutoff chosen to give a similar-sized group,
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Figure 3 Additional prognostic information is gained by combining assessment of eukaryotic translation initiation factor 4E (eIF4E)-binding proteins
(4E-BPs) with eIF4E analysis. Kaplan–Meier survival analyses of disease-free survival for patients with either high (6 or 7) eIF4E scores (A–C) or high (45.4)
Nottingham Prognostic Index scores (D–F). Patients were dichotomised using either eIF4E expression (A and D), the y function (which includes eIF4E
and 4E-BP2 scores) (B and E), or the z function (which includes scores for all 4 markers) (C and F).
Table 1 Expressions of eIF4E, 4E-BP1 and 4E-BP2 are positively
associated
eIF4E 4E-BP1 4E-BP2 p4E-BP1
eIF4E — 0.31 0.34 0.21
4E-BP1 0.31 — 0.37* 0.36
4E-BP2 0.34 0.37* — 0.14
P4E-BP1 0.21 0.36 0.14 —
Abbreviations: eIF4E¼eukaryotic translation initiation factor 4E; 4E-BP¼eIF4E-
binding protein; P4E-BP1¼phosphorylated 4E-BP1. Spearman’s r correlation figures
are shown. Associations are either moderately (*P¼0.02) or highly significant (others
Po0.0001).
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s38/282; 13.5%); finally (group 3), those with p4E-BP1 scores of 6 or
7 (26/282; 9.2%). We have examined whether biomarker choice
leads to selection of different potential treatment groups (Figure 4).
Substantially different patient groups were selected using each
potential predictive biomarker. Only 10 patients appeared in all
groups (16% of total patients selected in any group). Group 1
contained the largest proportion of uniquely selected individuals
(56% of total), whereas the majorities of groups 2 and 3 (74 and
81% respectively) overlapped with at least one other group. Group
2 (high z values) had large overlaps with both other groups (46% of
group 1 and 81% of group 3). In addition, group 2 included all
individuals with high eIF4E and p4E-BP1 (i.e. individuals likely to
have high eIF4E activity by all measures) reflecting the fact that z
successfully takes account of both eIF4E and p4E-BP1, thereby
supporting its utility as a potential predictive marker.
DISCUSSION
Expression of eIF4E in cancer has been studied extensively,
however, expression does not equate to activity; therefore,
interpretation of its influence is more complex than simply
assessing expression. Our hypothesis was that combined examina-
tion of eIF4E and its regulators would allow greater insights into
eIF4E’s influence on cancer. Therefore, we determined the
expression levels of eIF4E and its most well-established regulatory
proteins 4E-BP1, 4E-BP2 and p4E-BP1 within tumour cells of a
large cohort of cancer patients, and have combined these data into
an improved measure of prognosis and estimate of eIF4E activity.
In common with initial publications on eIF4E’s role in cancer
(Kerekatte et al, 1995; Li et al, 1998) and much of the subsequent
literature, we have focused on breast cancer.
There is a wealth of literature on eIF4E expression in cancer and,
although patient cohorts used have been relatively small (o200
individuals), the conclusion that high eIF4E levels are associated
with poor prognosis is well established (De Benedetti and Graff,
2004). We have also found this (Figure 2A–C) using the largest
cohort to date. The 4E-BPs have received less attention. 4E-BP1 is
more highly expressed in tumours than normal tissues (Salehi and
Mashayekhi, 2006), and expression correlates inversely with
tumour progression (Martin et al, 2000) – observations in
agreement with our findings. Despite the inverse correlation with
progression, we found examination of 4E-BP1 expression not to
give significant prognostic insights (Figure 2D, Supplementary
Figure S5A). To our knowledge, there are no published studies
concerning 4E-BP2 in cancer samples. We found that 4E-BP2
showed a nonsignificant trend for association with good prognosis
(Figure 2E, Supplementary Figure S5B). High p4E-BP1 levels have
earlier been shown to correlate with grade and poor prognosis
(Zhou et al, 2004; Castellvi et al, 2006; Rojo et al, 2007). In
contrast, we found detectable p4E-BP1 (Thr37/46) in only 37.7% of
the patients compared with 459% in other reports (Zhou et al,
2004; Rojo et al, 2007; Akcakanat et al, 2008)), and to provide little
prognostic power when analysed alone (Figure 2F, Supplementary
Figure S5C). We have carried out additional analyses with the same
antibody as reported earlier for p4E-BP1 (Ser65) (Zhou et al, 2004)
and similarly found low expression (50% undetectable, 28% the
lowest positive score). These differences may relate to the cohorts
used as earlier studies had higher proportions of node positive
(Zhou et al, 2004), subsequently metastatic (Akcakanat et al, 2008)
or high-grade cases (Rojo et al, 2007).
There are very few studies where multiple eIF4E pathway
components have been analysed. The ratios of p4E-BP1 to total 4E-
BP1 and of eIF4E to 4E-BP1 have been shown to correlate with
high tumour grade (Salehi and Mashayekhi, 2006; Armengol et al,
2007), but their relationships with survival were not examined. A
positive correlation between expression of eIF4E and p4E-BP1 has
also been noted, with the conclusion being that eIF4E was ‘active’
in these cells (Nathan et al, 2004). We have determined expression
levels of eIF4E, 4E-BP1, 4E-BP2, p4E-BP1 and have undertaken
analyses to relate these together and to survival. First, we found no
statistically significant relationship to survival for any combination
without including eIF4E – suggesting that eIF4E is the critical
effector. Second, in support of our initial hypothesis, we showed
that combined assessment of the four components allowed
improved prognostic insights over eIF4E alone (‘z’ function; text,
Figure 3). It is important to note that we did not predetermine
relationships between components in z, rather these were defined
by the best fit with the data; the fact that the relationships reflect
our expectations from understanding the pathway supports the
view that z is a true estimate of eIF4E activity. Third, we showed
differential expression of 4E-BP2 in cancer to be more influential
in terms of survival than 4E-BP1. This was shown by the
observations that expression of 4E-BP2, but not 4E-BP1, showed
a trend towards being a prognostic factor alone (Figure 2E,
Supplementary Figure S5B), provided an improved prognostic
indicator in combination with eIF4E (y), and was the most
statistically significant component of z after eIF4E itself. This
observation may relate to the fact that 4E-BP2 binds, and therefore
inhibits eIF4E more strongly than 4E-BP1 (Abiko et al, 2007).
Interestingly, we found that expressions of eIF4E and 4E-BPs were
positively associated (Table 1): an unexpected finding as they are
functionally opposed and correlate oppositely with grade. One
explanation is that 4E-BP translation may be specifically dere-
pressed by eIF4E’s action on the 50UTRs of their transcripts,
representing a negative feedback loop within the eIF4E pathway.
Clinical trials of the efficacy and safety of cancer therapeutics that
target eIF4E have been carried out (Graff et al, 2008) and some
toxicity has been reported (O’Donnell et al, 2008; Tabernero et al,
2008). Selection of individuals who are most likely to benefit from the
agents may be appropriate in order to avoid potentially harmful and/
or ineffective therapy in some patients. We show that substantially
different patient groups are chosen using three potential predictive
biomarkers, and therefore that use of the best biomarker is important
for targeting of these therapies (Figure 4). Patients with high
estimated eIF4E activity (‘z’) (group 2) and high p4E-BP1 levels
(group 3) should provide good candidates for treatment. The former
group has a particularly poor prognosis (Figure 3C and F), and
therefore great potential for clinical benefit from these drugs.
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